Vaxcyte – $690 Million Public Offering
Palo Alto – October 31, 2022 – A Cooley team advised Vaxcyte, a clinical-stage vaccine innovation company, on its underwritten public offering of common stock and pre-funded warrants, with aggregate gross proceeds to Vaxcyte of $690 million. Lawyers John McKenna, Mark Weeks and Julia Stark led the Cooley team advising Vaxcyte on the offering, while partner Mika Reiner Mayer led on intellectual property diligence for the company in connection with the transaction.
BofA Securities, Jefferies, SVB Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Cantor acted as lead manager, and Needham & Company and BTIG acted as co-managers.
Based in San Carlos, California, Vaxcyte works to rapidly engineer, optimize, and manufacture superior, high-fidelity vaccines at scale with the goal of eliminating invasive bacterial infections that have serious and costly health consequences.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of 3,300.